메뉴 건너뛰기




Volumn 65, Issue 1, 2013, Pages 61-68

Polycystic kidney disease: New horizons and therapeutic frontiers

Author keywords

Biological markers; Polycystic kidney, autosomal dominant; Therapeutics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; KD 019; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; OCTREOTIDE; PELITINIB; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; PYRIMETHAMINE; RAPAMYCIN; ROSCOVITINE; STAT3 PROTEIN; STAT6 PROTEIN; TOLVAPTAN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

EID: 84878762275     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (8)

References (58)
  • 1
    • 34047276812 scopus 로고    scopus 로고
    • Autosomal dominant polycystic kidney disease
    • DOI 10.1016/S0140-6736(07)60601-1, PII S0140673607606011
    • Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301. (Pubitemid 46552051)
    • (2007) Lancet , vol.369 , Issue.9569 , pp. 1287-1301
    • Torres, V.E.1    Harris, P.C.2    Pirson, Y.3
  • 2
  • 3
    • 79952276398 scopus 로고    scopus 로고
    • Epidemiological and molecular study of autosomal dominant polycystic kidney disease (ADPKD) in the province of Vicenza, Italy: Possible founder effect?
    • Corradi V, Gastaldon F, Virzì GM, Clementi M, Nalesso F, Cruz DN et al. Epidemiological and molecular study of autosomal dominant polycystic kidney disease (ADPKD) in the province of Vicenza, Italy: possible founder effect? G Ital Nefrol 2010;27:655-63.
    • (2010) G Ital Nefrol , vol.27 , pp. 655-663
    • Corradi, V.1    Gastaldon, F.2    Virzì, G.M.3    Clementi, M.4    Nalesso, F.5    Cruz, D.N.6
  • 4
    • 16244368607 scopus 로고    scopus 로고
    • Intraflagellar transport and cilia-dependent renal disease: The ciliary hypothesis of polycystic kidney disease
    • DOI 10.1097/01.ASN.0000141055.57643.E0
    • Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004;15:2528-36. (Pubitemid 41103359)
    • (2004) Journal of the American Society of Nephrology , vol.15 , Issue.10 , pp. 2528-2536
    • Pazour, G.J.1
  • 5
    • 0029069583 scopus 로고
    • The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains
    • Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millán JL et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995;10:151-60.
    • (1995) Nat Genet , vol.10 , pp. 151-160
    • Hughes, J.1    Ward, C.J.2    Peral, B.3    Aspinwall, R.4    Clark, K.5    San Millán, J.L.6
  • 6
    • 0029002967 scopus 로고
    • The International Polycystic Kidney Disease Consortium "Polycystic kidney disease: The complete structure of the PKD1 gene and its protein
    • [No authors listed]. The International Polycystic Kidney Disease Consortium
    • [No authors listed]. The International Polycystic Kidney Disease Consortium "Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995;81:289-98.
    • (1995) Cell , vol.81 , pp. 289-298
  • 11
    • 0037019017 scopus 로고    scopus 로고
    • Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease
    • DOI 10.1016/S0960-9822(02)00877-1
    • Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 2002;12:R378-80. (Pubitemid 34689219)
    • (2002) Current Biology , vol.12 , Issue.11
    • Pazour, G.J.1    San, A.J.T.2    Follit, J.A.3    Rosenbaum, J.L.4    Witman, G.B.5
  • 12
    • 0036785149 scopus 로고    scopus 로고
    • The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia
    • Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002;13:2508-16.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 2508-2516
    • Yoder, B.K.1    Hou, X.2    Guay-Woodford, L.M.3
  • 14
    • 34147215806 scopus 로고    scopus 로고
    • Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia
    • DOI 10.1128/MCB.00072-07
    • Wang S, Zhang J, Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007;27:3241-52. (Pubitemid 46581334)
    • (2007) Molecular and Cellular Biology , vol.27 , Issue.8 , pp. 3241-3252
    • Wang, S.1    Zhang, J.2    Nauli, S.M.3    Li, X.4    Starremans, P.G.5    Luo, Y.6    Roberts, K.A.7    Zhou, J.8
  • 15
    • 4644367485 scopus 로고    scopus 로고
    • Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype
    • DOI 10.1074/jbc.M405079200
    • Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004;279:40419-30. (Pubitemid 39287631)
    • (2004) Journal of Biological Chemistry , vol.279 , Issue.39 , pp. 40419-40430
    • Yamaguchi, T.1    Wallace, D.P.2    Magenheimer, B.S.3    Hempson, S.J.4    Grantham, J.J.5    Calvet, J.P.6
  • 16
    • 0029787141 scopus 로고    scopus 로고
    • The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro
    • Davidow CJ, Maser RL, Rome LA, Calvet JP, Grantham JJ. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996;50:208-18. (Pubitemid 26323715)
    • (1996) Kidney International , vol.50 , Issue.1 , pp. 208-218
    • Davidow, C.J.1    Maser, R.L.2    Rome, L.A.3    Calvet, J.P.4    Grantham, J.J.5
  • 18
    • 29744470060 scopus 로고    scopus 로고
    • Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease
    • DOI 10.1016/j.devcel.2005.12.005, PII S1534580705004818
    • Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT et at. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 2006;10:57-69. (Pubitemid 43025677)
    • (2006) Developmental Cell , vol.10 , Issue.1 , pp. 57-69
    • Low, S.H.1    Vasanth, S.2    Larson, C.H.3    Mukherjee, S.4    Sharma, N.5    Kinter, M.T.6    Kane, M.E.7    Obara, T.8    Weimbs, T.9
  • 20
    • 33645769011 scopus 로고    scopus 로고
    • The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
    • Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006;103:5466-71.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 5466-5471
    • Shillingford, J.M.1    Murcia, N.S.2    Larson, C.H.3    Low, S.H.4    Hedgepeth, R.5    Brown, N.6
  • 21
    • 77949528561 scopus 로고    scopus 로고
    • Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR
    • Dere R, Wilson PD, Sandford RN, Walker CL. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 2010;5:e9239.
    • (2010) PLoS One , vol.5
    • Dere, R.1    Wilson, P.D.2    Sandford, R.N.3    Walker, C.L.4
  • 22
    • 65449176538 scopus 로고    scopus 로고
    • Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1
    • Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009;29:2359-71.
    • (2009) Mol Cell Biol , vol.29 , pp. 2359-2371
    • Distefano, G.1    Boca, M.2    Rowe, I.3    Wodarczyk, C.4    Ma, L.5    Piontek, K.B.6
  • 23
    • 0035019467 scopus 로고    scopus 로고
    • Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene
    • DOI 10.1016/S1097-2765(01)00226-X
    • Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K et al. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 2001;7:823-32. (Pubitemid 32436442)
    • (2001) Molecular Cell , vol.7 , Issue.4 , pp. 823-832
    • Kleymenova, E.1    Ibraghimov-Beskrovnaya, O.2    Kugoh, H.3    Everitt, J.4    Xu, H.5    Kiguchi, K.6    Landes, G.7    Harris, P.8    Walker, C.9
  • 25
    • 20944435539 scopus 로고    scopus 로고
    • Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways
    • Simons M, Gloy J, Gartner A, Bullerkotte A, Bashkurov M, Krönig C et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 2005;37:537-43.
    • (2005) Nat Genet , vol.37 , pp. 537-543
    • Simons, M.1    Gloy, J.2    Gartner, A.3    Bullerkotte, A.4    Bashkurov, M.5    Krönig, C.6
  • 26
    • 84859264546 scopus 로고    scopus 로고
    • The ciliary transition zone: From morphology and molecules to medicine
    • Czarnecki PG, Shah JV. The ciliary transition zone: from morphology and molecules to medicine. Trends Cell Biol 2012;22:201-10.
    • (2012) Trends Cell Biol , vol.22 , pp. 201-210
    • Czarnecki, P.G.1    Shah, J.V.2
  • 28
    • 33646710257 scopus 로고    scopus 로고
    • Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes
    • Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-57.
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 148-157
    • Grantham, J.J.1    Chapman, A.B.2    Torres, V.E.3
  • 29
    • 79951674629 scopus 로고    scopus 로고
    • mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression
    • Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011;79:502-11.
    • (2011) Kidney Int , vol.79 , pp. 502-511
    • Huber, T.B.1    Walz, G.2    Kuehn, E.W.3
  • 30
    • 47249117032 scopus 로고    scopus 로고
    • Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD
    • Moreno S, Ibraghimov-Beskrovnaya O, Bukanov NO. Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle 2008;7:1856-64. (Pubitemid 351988752)
    • (2008) Cell Cycle , vol.7 , Issue.12 , pp. 1856-1864
    • Moreno, S.1    Ibraghimov-Beskrovnaya, O.2    Bukanov, N.O.3
  • 31
    • 33751412843 scopus 로고    scopus 로고
    • Urinary proteomic profiles distinguish between active and inactive lupus nephritis
    • DOI 10.1093/rheumatology/kel351
    • Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 2006;45:1497-504. (Pubitemid 44817055)
    • (2006) Rheumatology , vol.45 , Issue.12 , pp. 1497-1504
    • Mosley, K.1    Tam, F.W.K.2    Edwards, R.J.3    Crozier, J.4    Pusey, C.D.5    Lightstone, L.6
  • 34
    • 84878757664 scopus 로고    scopus 로고
    • Develop biomarkers to aid in the development of therapies for polycystic kidney disease (PKD)
    • USDA. Washington, D.C.: U.S. Department of Health and Human Services Food and Drug Administration; June
    • USDA. Develop biomarkers to aid in the development of therapies for polycystic kidney disease (PKD). In Key FDA critical path activities under way in 2007. Washington, D.C.: U.S. Department of Health and Human Services Food and Drug Administration; June 2008. p. 5.
    • (2008) Key FDA Critical Path Activities under Way in 2007 , pp. 5
  • 36
    • 54849146500 scopus 로고    scopus 로고
    • Clinical practice. Autosomal dominant polycystic kidney disease
    • Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-85.
    • (2008) N Engl J Med , vol.359 , pp. 1477-1485
    • Grantham, J.J.1
  • 41
    • 38149005366 scopus 로고    scopus 로고
    • Vasopressin directly regulates cyst growth in polycystic kidney disease
    • Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-8.
    • (2008) J Am Soc Nephrol , vol.19 , pp. 102-108
    • Wang, X.1    Wu, Y.2    Ward, C.J.3    Harris, P.C.4    Torres, V.E.5
  • 42
    • 0142073812 scopus 로고    scopus 로고
    • Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
    • DOI 10.1038/nm935
    • Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-6. (Pubitemid 37279858)
    • (2003) Nature Medicine , vol.9 , Issue.10 , pp. 1323-1326
    • Gattone II, V.H.1    Wang, X.2    Harris, P.C.3    Torres, V.E.4
  • 43
    • 79954622171 scopus 로고    scopus 로고
    • Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study
    • Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT et al. "Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011;57:692-9.
    • (2011) Am J Kidney Dis , vol.57 , pp. 692-699
    • Torres, V.E.1    Meijer, E.2    Bae, K.T.3    Chapman, A.B.4    Devuyst, O.5    Gansevoort, R.T.6
  • 44
    • 80053904548 scopus 로고    scopus 로고
    • TEMPOFormula and 156-05-002 Study Investigators: Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience
    • Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ et al. TEMPOFormula and 156-05-002 Study Investigators: Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011;6:2499-507.
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 2499-2507
    • Higashihara, E.1    Torres, V.E.2    Chapman, A.B.3    Grantham, J.J.4    Bae, K.5    Watnick, T.J.6
  • 45
    • 79960426743 scopus 로고    scopus 로고
    • Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
    • Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80:295-301.
    • (2011) Kidney Int , vol.80 , pp. 295-301
    • Irazabal, M.V.1    Torres, V.E.2    Hogan, M.C.3    Glockner, J.4    King, B.F.5    Ofstie, T.G.6
  • 46
    • 69249235445 scopus 로고    scopus 로고
    • A case for water in the treatment of polycystic kidney disease
    • Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50.
    • (2009) Clin J Am Soc Nephrol , vol.4 , pp. 1140-1150
    • Torres, V.E.1    Bankir, L.2    Grantham, J.J.3
  • 47
    • 77950942370 scopus 로고    scopus 로고
    • A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease
    • Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:693-7.
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 693-697
    • Barash, I.1    Ponda, M.P.2    Goldfarb, D.S.3    Skolnik, E.Y.4
  • 49
    • 77952965873 scopus 로고    scopus 로고
    • Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease
    • Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-61.
    • (2010) J Am Soc Nephrol , vol.21 , pp. 1052-1061
    • Hogan, M.C.1    Masyuk, T.V.2    Page, L.J.3    Kubly, V.J.4    Bergstralh, E.J.5    Li, X.6
  • 52
    • 77956029702 scopus 로고    scopus 로고
    • Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
    • Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363.820-9.
    • (2010) N Engl J Med , vol.363 , pp. 820-829
    • Serra, A.L.1    Poster, D.2    Kistler, A.D.3    Krauer, F.4    Raina, S.5    Young, J.6
  • 53
    • 77954770878 scopus 로고    scopus 로고
    • Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases
    • Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29.
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1312-1329
    • Torres, V.E.1    Boletta, A.2    Chapman, A.3    Gattone, V.4    Pei, Y.5    Qian, Q.6
  • 55
    • 48149087107 scopus 로고    scopus 로고
    • Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease
    • Yang B, Sonawane ND, Zhao D, SomLo S, Verkman AS. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:1300-10.
    • (2008) J Am Soc Nephrol , vol.19 , pp. 1300-1310
    • Yang, B.1    Sonawane, N.D.2    Zhao, D.3    SomLo, S.4    Verkman, A.S.5
  • 56
    • 33845909549 scopus 로고    scopus 로고
    • Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine
    • DOI 10.1038/nature05348, PII NATURE05348
    • Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006;444:949-52. (Pubitemid 46025010)
    • (2006) Nature , vol.444 , Issue.7121 , pp. 949-952
    • Bukanov, N.O.1    Smith, L.A.2    Klinger, K.W.3    Ledbetter, S.R.4    Ibraghimov- Beskrovnaya, O.5
  • 57
    • 79955780675 scopus 로고    scopus 로고
    • Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model
    • Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011;300:F1193-202.
    • (2011) Am J Physiol Renal Physiol , vol.300
    • Leonhard, W.N.1    Van Der Wal, A.2    Novalic, Z.3    Kunnen, S.J.4    Gansevoort, R.T.5    Breuning, M.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.